Similar articles

• Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?

  McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ. McMurray JJ, et al. Circulation. 2004 Nov 16;110(20):3281-8. doi: 10.1161/01.CIR.0000147274.83071.68. Circulation. 2004. PMID: 15545527 Review. No abstract available.
• [Neurohumoral blocking agents].

  Kurisu S, Kihara Y. Kurisu S, et al. Nihon Rinsho. 2011 Nov;69 Suppl 9:394-6. Nihon Rinsho. 2011. PMID: 22724235 Review. Japanese. No abstract available.
• Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.

  Lenzen MJ, Boersma E, Reimer WJ, Balk AH, Komajda M, Swedberg K, Follath F, Jimenez-Navarro M, Simoons ML, Cleland JG. Lenzen MJ, et al. Eur Heart J. 2005 Dec;26(24):2706-13. doi: 10.1093/eurheartj/ehi499. Epub 2005 Sep 23. Eur Heart J. 2005. PMID: 16183692
• Heart failure: recent advances in prevention and treatment.

  Fonarow GC. Fonarow GC. Rev Cardiovasc Med. 2000 Summer;1(1):25-33, 54. Rev Cardiovasc Med. 2000. PMID: 12457149 Review.
• [Recent advances and limitations of medical treatment on heart failure].

  Momomura S. Momomura S. Kyobu Geka. 2007 Jun;60(6):484-7. Kyobu Geka. 2007. PMID: 17564066 Japanese.